Form 8-K CYTOKINETICS INC For: Oct 27

Go back to Form 8-K CYTOKINETICS INC For: Oct 27

Roth Capital Maintains Cytokinetics (CYTJK) at 'Buy' Amid Encouraging COSMIC-HF Data

October 27, 2015 2:52 PM EDT

Roth Capital affirms Cytokinetics (Nasdaq: CYTK) with a Buy rating and $18 price target after the company and Amgen (Nasdaq: AMGN)... More